Skip to content
Research Article Open access CC BY 4.0

Impact of Combining Immune Checkpoint Inhibitors with Chemotherapy in the Management of Advanced Serous Endometrial Adenocarcinoma

Hamadoun Traoré, Andy J Kouanga, Choukri Elm’hadi, Ait Sahel Omar, Rachid Tanz, Hassan Errihani

Journal of Advances in Medicine and Medical Research · pp. 188–192 · Published 2 Jun 2024

10.9734/jammr/2024/v36i65463

Abstract

Chemo-immunotherapy is a relatively recent approach to the treatment of advanced or relapsed endometrial cancer. The aim of these therapies is to remove immune suppression, enabling the immune system to better recognise and destroy cancer cells. We report a clinical case of stage 4 endometrial cancer in a 69-year-old patient with several commorbidities in whom we obtained a complete response after four cycles of paclitaxel+carboplatin combined with pembrolizumab followed by maintenance immunotherapy. Immunotherapy combined with chemotherapy is a relatively recent approach to the treatment of advanced or relapsed endometrial cancer. This case report demonstrates the importance of adding immunotherapy to chemotherapy in the management of advanced endometrial cancer.

Advanced endometrial cancer immunotherapy chemotherapy

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

21

Page views

0

PDF downloads

2

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.